FDG-PET in the Diagnosis of Autoimmune Encephalitis

Status: Recruiting
Location: See all (6) locations...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

The goal of this retrospective observational study is to compare brain fluorodeoxyglucose-positron emission tomography (FDG-PET) of patients with autoimmune encephalitis, normal controls and patients with Alzheimer's disease (AD). The main question it aims to answer is: •is there a specific pattern of brain metabolism in patients with autoimmune encephalitis Participants data and images will be retrospectively collected from hospital records, and FDG-PET images will be analyzed by means of statistical parametric mapping (SPM). Controls will be selected from validated public databases.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Diagnosis of autoimmune encephalitis according to clinical criteria

• Brain magnetic resonance imaging performed between clinical presentation and treatment

• Cerebrospinal fluid analysis performed between clinical presentation and treatment

• Brain FDG-PET performed between clinical presentation and treatment

• Autoantibodies testing performed between clinical presentation and treatment

Locations
Other Locations
Italy
IRCCS Ospedale Policlinico San Martino
NOT_YET_RECRUITING
Genoa
Fondazione IRCCS Istituto Neurologico Carlo Besta
NOT_YET_RECRUITING
Milan
Ospedale San Paolo
NOT_YET_RECRUITING
Milan
Fondazione IRCCS San Gerardo dei Tintori
RECRUITING
Monza
Fondazione IRCCS Mondino
RECRUITING
Pavia
Azienda Sanitaria Universitaria Friuli Centrale
NOT_YET_RECRUITING
Udine
Contact Information
Primary
Simone Beretta, MD, PhD
simone.beretta@unimib.it
+390392333568
Backup
Federico Emanuele Pozzi, MD
federicoemanuele.pozzi@gmail.com
Time Frame
Start Date: 2023-03-01
Estimated Completion Date: 2024-04-30
Participants
Target number of participants: 90
Treatments
Autoimmune Encephalitis patients
Patients with autoimmune encephalitis admitted to the centers, who underwent a brain FDG-PET during the course of their disease trajectory.
Sponsors
Leads: University of Milano Bicocca

This content was sourced from clinicaltrials.gov